Literature DB >> 8994420

Single LDL apheresis improves endothelium-dependent vasodilatation in hypercholesterolemic humans.

O Tamai1, H Matsuoka, H Itabe, Y Wada, K Kohno, T Imaizumi.   

Abstract

BACKGROUND: Although long-term lipid-lowering therapy improves endothelium-dependent vasodilatation in humans, it remains unknown whether the short-term removal of LDL per se ameliorates endothelial dysfunction. METHODS AND
RESULTS: To examine the effects of a single session of LDL apheresis on endothelial function in patients with hypercholesterolemia, we measured forearm blood flow (FBF) by strain-gauge plethysmography before and after single LDL apheresis while infusing acetylcholine (ACh; 4 to 24 micrograms/min) and sodium nitroprusside (SNP; 0.2 to 1.2 micrograms/min). The single session of LDL apheresis reduced total LDL (from 142.2 +/- 15.0 to 32.6 +/- 5.0 mg/mL, P < .0005) and oxidized LDL (from 111.6 +/- 22.8 to 30.0 +/- 5.4 ng/mL, P < .005). Although ACh and SNP increased FBF dose-dependently before and after LDL apheresis, the endothelium-dependent vasodilatation responses to ACh were significantly augmented (P < .01) after the single session of LDL apheresis without changes in the endothelium-independent vasodilatation responses to SNP. The plasma levels of total and oxidized LDL correlated with the degree of ACh-induced vasodilatation. Furthermore, the local production of nitrate/nitrite, metabolites of NO, during ACh infusion was significantly (P < .05) augmented by LDL apheresis, and there was a significant correlation between the degree of ACh-induced vasodilatation and the production in nitrate/nitrite (r = .99, P < .0005).
CONCLUSIONS: We demonstrated that even a single session of LDL apheresis with the reduction of total LDL and oxidized LDL improved endothelial function. Our results suggest that total LDL and/or oxidized LDL may directly impair endothelial function in the human forearm vessel.

Entities:  

Mesh:

Substances:

Year:  1997        PMID: 8994420     DOI: 10.1161/01.cir.95.1.76

Source DB:  PubMed          Journal:  Circulation        ISSN: 0009-7322            Impact factor:   29.690


  69 in total

Review 1.  Incorporation of low-density lipoprotein apheresis into the treatment program of patients with severe hypercholesterolemia.

Authors:  B R Gordon
Journal:  Curr Atheroscler Rep       Date:  2000-07       Impact factor: 5.113

Review 2.  [Plaque stabilization and endothelial protection by cholesterol synthesis inhibitors].

Authors:  D Müller-Wieland; M Faust; J Kotzka; W Krone
Journal:  Herz       Date:  1999-05       Impact factor: 1.443

Review 3.  [Plaque stabilization by LDL apheresis?].

Authors:  P Schuff-Werner; V Schettler
Journal:  Herz       Date:  1999-02       Impact factor: 1.443

Review 4.  Venous occlusion plethysmography in cardiovascular research: methodology and clinical applications.

Authors:  I B Wilkinson; D J Webb
Journal:  Br J Clin Pharmacol       Date:  2001-12       Impact factor: 4.335

Review 5.  Lipids and endothelium-dependent vasodilation--a review.

Authors:  Lars Lind
Journal:  Lipids       Date:  2002-01       Impact factor: 1.880

Review 6.  [Non-lipid effects of statins: myth or fact?].

Authors:  Eleonora Urbauer; Christian Joukhadar
Journal:  Wien Med Wochenschr       Date:  2003

Review 7.  Isoprenoid metabolism and the pleiotropic effects of statins.

Authors:  Ulrich Laufs; James K Liao
Journal:  Curr Atheroscler Rep       Date:  2003-09       Impact factor: 5.113

Review 8.  Exercise and the nitric oxide vasodilator system.

Authors:  Andrew Maiorana; Gerard O'Driscoll; Roger Taylor; Daniel Green
Journal:  Sports Med       Date:  2003       Impact factor: 11.136

9.  Effect of treatment with pravastatin or ezetimibe on endothelial function in patients with moderate hypercholesterolemia.

Authors:  Liliana Grigore; Sara Raselli; Katia Garlaschelli; Laura Redaelli; Giuseppe D Norata; Angela Pirillo; Alberico L Catapano
Journal:  Eur J Clin Pharmacol       Date:  2012-07-10       Impact factor: 2.953

Review 10.  Pleiotropic effects of statins: moving beyond cholesterol control.

Authors:  Paul J Garcia
Journal:  Curr Atheroscler Rep       Date:  2005-02       Impact factor: 5.113

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.